Dishman Pharma is a smart gainer on the bourses currently. The stock price is up over 3% at Rs.355 an this is after an intra day high at Rs.357.65.

The stock is up, happy with its announcement that that the Management Committee of Board of Directors of the Company have approved and fixed May 03, 2016 as the Record Date for the purpose of deciding the members who shall be eligible for allotment of the Bonus shares in the proportion of 1 (One) Bonus Equity Share of Rs. 2/- (Rupees Two only) each, for every 1 (One) fully paid-up Equity Share of Rs. 2/- (Rupees Two only) each.

For Q3Fy16, the company had shown a whopping 95% (YoY) jump in net profit at Rs.469 crore and this was despite a 0.2% fall in net sales at Rs.3887 crore. Cost control and mainly reduction in debt and consequently interest outgo is what helped. Its EBITDA margin for the quarter jumped up from 19% to 28%.

Its interest expense declined by 28%, driven by lower debt. Total debt declined by 8% on YTD basis to Rs.855 crore. Conversion of certain rupee loans into foreign currency loans and repayment of high cost debt also helped bring down the cost.